Literature DB >> 24370691

The impact of type 2 diabetes on the outcome of localized renal cell carcinoma.

Thomas Höfner1, Martin Zeier, Gencay Hatiboglu, Christian Eisen, Gita Schönberg, Boris Hadaschik, Dogu Teber, Stefan Duensing, Andreas Trumpp, Markus Hohenfellner, Sascha Pahernik.   

Abstract

PURPOSE: To evaluate the influence of type 2 diabetes on cancer-specific outcome in patients undergoing surgery for localized renal cell carcinoma (RCC).
METHODS: A total of 1,140 patients with localized RCC undergoing radical or partial nephrectomy were enrolled into this retrospective case-control study. Primary outcome was the cancer-specific survival comparing patients with and without type 2 diabetes at the time of surgery. Secondary outcomes were recurrence-free survival and metastases-free survival comparing the same groups. Additionally, the influence of accompanying factors on cancer-specific survival and overall survival of patients was evaluated in a multivariate analysis. Among 1,140 patients included in the analyses, 202 had diabetes at the time of surgery and 938 patients without diabetes served as control.
RESULTS: The univariate comparisons between patients with and without diabetes regarding recurrence-free, metastases-free, and cancer-specific survival revealed no significant differences. Multivariate results demonstrate that age, BMI, and diabetes had no significant effect on cancer-specific hazard among participants. After adjustment of the factors in terms of overall survival, however, increased age, increased BMI, and type 2 diabetes at the time of surgery were independent risk factors for the occurrence of the event death.
CONCLUSIONS: Type 2 diabetes and obesity at the time of surgery have no significant impact on cancer-specific and recurrence-free survival in patients with localized renal cancer.

Entities:  

Mesh:

Year:  2013        PMID: 24370691     DOI: 10.1007/s00345-013-1231-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  29 in total

1.  Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study.

Authors:  Alessandro Antonelli; Nicola Arrighi; Serena Corti; Tiziano Zanotelli; Alberto Cozzoli; Sergio Cosciani Cunico; Claudio Simeone
Journal:  Urol Oncol       Date:  2012-01-24       Impact factor: 3.498

2.  Compared to what? Finding controls for case-control studies.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

3.  Graphical methods for assessing violations of the proportional hazards assumption in Cox regression.

Authors:  K R Hess
Journal:  Stat Med       Date:  1995-08-15       Impact factor: 2.373

4.  Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension.

Authors:  Christopher P Filson; Kendra Schwartz; Joanne S Colt; Julie Ruterbusch; W Marston Linehan; Wong-Ho Chow; David C Miller
Journal:  Urol Oncol       Date:  2013-02-16       Impact factor: 3.498

5.  Diabetes and cancer: a consensus report.

Authors:  Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee
Journal:  CA Cancer J Clin       Date:  2010-06-16       Impact factor: 508.702

Review 6.  Diabetes and hypertension: the bad companions.

Authors:  Ele Ferrannini; William C Cushman
Journal:  Lancet       Date:  2012-08-11       Impact factor: 79.321

7.  Diabetes mellitus with obesity is a predictor of recurrence in patients with non-metastatic renal cell carcinoma.

Authors:  Hiroshi Fukushima; Hitoshi Masuda; Minato Yokoyama; Manabu Tatokoro; Soichiro Yoshida; Junichiro Ishioka; Yoh Matsuoka; Noboru Numao; Fumitaka Koga; Kazutaka Saito; Yasuhisa Fujii; Kazunori Kihara
Journal:  Jpn J Clin Oncol       Date:  2013-05-31       Impact factor: 3.019

Review 8.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants.

Authors:  Goodarz Danaei; Mariel M Finucane; Yuan Lu; Gitanjali M Singh; Melanie J Cowan; Christopher J Paciorek; John K Lin; Farshad Farzadfar; Young-Ho Khang; Gretchen A Stevens; Mayuree Rao; Mohammed K Ali; Leanne M Riley; Carolyn A Robinson; Majid Ezzati
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

9.  Effect of type 2 diabetes mellitus on prognosis of nonmetastatic renal cell cancer.

Authors:  Evren Süer; Erdem Oztürk; Omer Gülpınar; Aytaç Kayış; Sümer Baltacı
Journal:  Korean J Urol       Date:  2013-08-07

10.  Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis.

Authors:  Satoru Kodama; Shiro Tanaka; Yoriko Heianza; Kazuya Fujihara; Chika Horikawa; Hitoshi Shimano; Kazumi Saito; Nobuhiro Yamada; Yasuo Ohashi; Hirohito Sone
Journal:  Diabetes Care       Date:  2013-02       Impact factor: 19.112

View more
  9 in total

1.  The prognostic significance of preexisting diabetes in patients with surgically treated renal cell carcinoma: the ongoing debate.

Authors:  Ho Won Kang; Yong-June Kim
Journal:  Ann Transl Med       Date:  2019-12

2.  Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma.

Authors:  Maximilian Christian Kriegmair; Philipp Mandel; Stefan Porubsky; Julia Dürr; Nina Huck; Philipp Nuhn; Daniel Pfalzgraf; Maurice Stephan Michel; Nina Wagener
Journal:  Horm Cancer       Date:  2017-02-28       Impact factor: 3.869

3.  Diabetes and kidney cancer outcomes: a propensity score analysis.

Authors:  Madhur Nayan; Antonio Finelli; Michael A S Jewett; David N Juurlink; Peter C Austin; Girish S Kulkarni; Robert J Hamilton
Journal:  Endocrine       Date:  2016-11-04       Impact factor: 3.633

4.  Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies.

Authors:  Rebecca E Graff; Alejandro Sanchez; Deirdre K Tobias; Dayron Rodríguez; Glen W Barrisford; Michael L Blute; Yanping Li; Qi Sun; Mark A Preston; Kathryn M Wilson; Eunyoung Cho
Journal:  Diabetes Care       Date:  2018-04-20       Impact factor: 19.112

5.  Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau).

Authors:  Marco Randazzo; Josef Beatrice; Andreas Huber; Rainer Grobholz; Lukas Manka; Stephen F Wyler; Felix F Chun; Franz Recker; Maciej Kwiatkowski
Journal:  World J Urol       Date:  2014-10-31       Impact factor: 4.226

6.  The Impact of Diabetes Mellitus on Renal Cell Carcinoma Prognosis: A Meta-Analysis of Cohort Studies.

Authors:  Luyao Chen; Hongzhao Li; Liangyou Gu; Xin Ma; Xintao Li; Yu Gao; Yu Zhang; Donglai Shen; Yang Fan; Baojun Wang; Xu Bao; Xu Zhang
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

7.  Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma.

Authors:  Antonio Vavallo; Simona Simone; Giuseppe Lucarelli; Monica Rutigliano; Vanessa Galleggiante; Giuseppe Grandaliano; Loreto Gesualdo; Marcello Campagna; Marica Cariello; Elena Ranieri; Giovanni Pertosa; Gaetano Lastilla; Francesco Paolo Selvaggi; Pasquale Ditonno; Michele Battaglia
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

8.  Insulin receptor expression in clear cell renal cell carcinoma and its relation to prognosis.

Authors:  Sayamaa Lkhagvadorj; Sung Soo Oh; Mi-Ra Lee; Jae Hung Jung; Hyun Chul Chung; Seung-Kuy Cha; Minseob Eom
Journal:  Yonsei Med J       Date:  2014-07       Impact factor: 2.759

9.  Diabetes, prediabetes and the survival of nasopharyngeal carcinoma: a study of 5,860 patients.

Authors:  Pu-Yun OuYang; Zhen Su; Jie Tang; Xiao-Wen Lan; Yan-Ping Mao; Wuguo Deng; Fang-Yun Xie
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.